ASX Release

11 August 2016

Correction of link to HepaFat-Scan® publication

Please note the following correction of the link to the HepaFat-Scan publication in the ASX announcement released earlier today:

"HepaFat-Scan® Accuracy and Repeatability Confirmed in International Scientific Journal"

The link below replaces the link in the earlier announcement:

Please click here to access the international publication.

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160789

For further information please contact:
Sander Bangma
General Manager, Resonance Health
E: SanderB@resonancehealth.com P: +61 (0)8 92865300

ASX Release

11 August 2016

HepaFat-Scan® Accuracy and Repeatability Confirmed in International Scientific Journal

Resonance Health (ASX: RHT) today announced that the results of the pivotal clinical study assessing the accuracy of Resonance Health's FDA approved HepaFat-Scan technology were published in the international scientific journal PLoS ONE. The news is an important milestone for HepaFat-Scan since it provides direct evidence of the performance and reliability of the technology and lays a solid foundation for uptake of HepaFat-Scan in the clinical community. HepaFat-Scan enables the measurement of volumetric liver fat fraction (VLFF) from magnetic resonance (MR) images, without the need for an invasive liver biopsy; the current gold standard.

The study results demonstrate that HepaFat-Scan has a very high degree of accuracy and repeatability and that it is directly comparable to liver biopsy. HepaFat-Scan is currently the only MR technique for measuring volumetric liver fat fraction that can be directly compared to biopsy, and as such it has a significant competitive advantage over alternative techniques. This advantage is being recognised in the clinical and pharmaceutical community and has resulted in collaborations with global Key Opinion Leaders in the field who are applying HepaFat-Scan in several clinical studies worldwide.

Resonance Health's participation in the studies aims to collect supporting data and evidence on the effectiveness of HepaFat-Scan in a range of indications. HepaFat-Scan is being used in both adult and paediatric populations to diagnose and monitor fatty liver disease. Additionally, HepaFat-Scan is being trialed in pre-surgical assessments for patients with colorectal metastatic liver cancer, diabetic patients, and in monitoring the results of bariatric surgery.

The Company is also engaged in discussions with pharmaceutical companies who are actively developing therapeutic compounds to target fatty liver disease. Resonance Health has extensive experience in the provision of imaging core laboratory services to large pharmaceutical companies and is ideally positioned to provide HepaFat-Scan in this setting, as well as in the wider clinical community for routine patient diagnosis, monitoring and management.

There is a global epidemic of fatty liver disease worldwide, with an estimated 20 - 30% of the population of the United States having fatty liver disease, with similar prevalence estimates for Europe, Asia and Australia. These figures are of great concern since a significant fraction of people with fatty liver will go on to develop a serious liver condition known as non-alcoholic steatohepatitis (NASH). In conjunction with another of Resonance Health's technologies, FerriScan®, HepaFat-Scan is also being evaluated for use in resolving the underlying causes of the common condition, unexplained hyperferritinaemia.

Resonance Health Ltd.
278 Stirling Hwy, Claremont, WA 6010, AUSTRALIA Postal: PO Box 1135, Nedlands, WA, 6909, AUSTRALIA
W www.resonancehealth.com **T** + 61 8 9286 5300 **E** info@resonancehealth.com

The benefits of the combined use of FerriScan and HepaFat-Scan in diagnosing unexplained hyperferritinaemia have recently been recognised and presented by a leading Haematologist, which is an important step towards further adoption in this field.

HepaFat-Scan is a new tool for the medical community who are seeking to understand and manage fatty liver disease in patients worldwide. It is expected to make a positive global contribution to the management of the fatty liver disease epidemic and associated conditions.

Please click here to access the international publication.

For further information please contact:

Sander Bangma
General Manager, Resonance Health
E: SanderB@resonancehealth.com P: +61 (0)8 92865300